MA
MaaT Pharma S.A.
MAAT.PA · PAR
2.77 € -0.72% (-0.02 €)
1M -7.12%
Market Cap 52.9M €
P/E Ratio -
Div. Yield -
ROE 269.86%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 11.69x
P/B 29.39x
P/E N/A
Growth
78 /100
Growing Rev. growth 46.80%
Book val. growth 59.36%
EPS growth N/A
Profitability
11 /100
Weak Gross margin 30.70%
FCF margin 365.21%
Net margin 686.58%
Quality
1 /100
Poor ROIC 101.22%
Asset turnover 0.10x
ROE 269.86%
Debt
22 /100
High Debt/Equity 9.69x
Int. coverage -26.91x
Current ratio 1.94x
Stability
69 /100
Stable Beta 0.41x
Profitable years 0
Rev. volatility 7.89%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MAAT.PA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Herve Affagard
Employees
56
Headquarters
Lyon
Prihajajoči dogodki
29 SEP.
Earnings
Upcoming earnings report